<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> can be treated with either bone marrow transplantation (BMT) or immunosuppressive therapy (IST) </plain></SENT>
<SENT sid="1" pm="."><plain>A retrospective review of patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> treated with both of these modalities was conducted </plain></SENT>
<SENT sid="2" pm="."><plain>Fifteen BMT and 16 IST patients were available for analysis, and follow-up of 22 and 15 years was available for the BMT and IST groups, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Median survival was limited to 4.3 months in BMT patients vs. 135.2 months in IST patients, despite the older median age of the latter (22 vs. 55 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Actuarial survival at 1 and 5 years was 87% and 78% for the IST patients and 40% and 33% for the BMT patients </plain></SENT>
<SENT sid="5" pm="."><plain>Hematologic response rates, as defined by achievement of transfusion independence, were similar for the two groups </plain></SENT>
<SENT sid="6" pm="."><plain>Long-term responses and survival are possible with antithymocyte globulin/<z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
</text></document>